Autonomix Medical Granted New European Patent

Autonomix Medical Inc.’s patent tally has topped 80.

The company has been awarded a new European patent for its catheter-based technology. Patent No. 3,697,298 (the ‘298 patent), “Medical Device with Circuitry for Capturing and Processing Physiological Signals,” relates to use of its proprietary technology to collect and process sensing data for real-time physiological monitoring with broad applications.

Those applications include coronary artery/vagal nerve mapping, arterial/renal mapping, bladder/lower urinary tract applications, robotic prosthetics and implants, and central nervous system monitoring for neurotherapy.

“By protecting our proprietary circuitry for capturing and processing physiological signals in real time, we continue to strengthen the competitive moat around our technology which has broad, high-value applications across a number of indications. The ‘298 patent combined with 80 other issued patents positions us to capture opportunities across multiple multi-billion-dollar markets, create diverse revenue streams, and expand our global footprint as we advance toward potential commercialization in the future,” Autonomix CEO Brad Hauser said.

The ‘298 patent particularly relates generally to medical devices and methods for acquiring and processing physiological signals and provides a system of distributed signal acquisition modules that enhance signal capture and data integrity during neural mapping procedures. These modules locally capture, amplify, digitize, and transmit physiological signals from sensors arranged along the catheter. Key elements of the technology include, but are not limited to, multiple processing modules paired to one or more sensor, data acquisition logic, analog and digital signal processing circuitry positioned at the source, efficient data transmitting, and a modular microchip design, along with technical advantages that range from miniaturization to precision to noise reduction.

Autonomix’s first-in-class technology platform utilizes a catheter-based microchip sensing array antenna that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. Once target nerves are identified, Autonomix uses its proprietary RF ablation technology to kill targeted nerves, enabling a precision guided sense, treat and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology.

Autonomix is a medical device company focused on advancing technologies to revolutionize the ways in which nervous system diseases are diagnosed and treated. The company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may be able to detect and differentiate neural signals with greater sensitivity than currently available technologies. This will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

Autonomix is initially developing this technology for pain treatment, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. The technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension, and chronic pain management, across a wide disease spectrum. The technology is investigational and has not yet been cleared for marketing in the United States.